Dr. Sanford Markowitz (IMAGE)
Caption
“Encouragingly, both pharmaceutical and biotechnology companies have initiated development of 15-PGDH inhibitors for peripheral indications, and inhibitor MF-300 has already completed Phase 1 clinical trials. Our results now provide the rationale to repurpose such agents for the treatment of PD,” Dr. Markowitz said.
Credit
University Hospitals / CWRU
Usage Restrictions
N/A
License
Original content